Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes
Top Cited Papers
Open Access
- 1 March 2017
- journal article
- research article
- Published by Mary Ann Liebert Inc in Diabetes Technology & Therapeutics
- Vol. 19 (3), 155-163
- https://doi.org/10.1089/dia.2016.0421
Abstract
Background: The safety and effectiveness of the in-home use of a hybrid closed-loop (HCL) system that automatically increases, decreases, and suspends insulin delivery in response to continuous glucose monitoring were investigated. Methods: Adolescents (n = 30, ages 14–21 years) and adults (n = 94, ages 22–75 years) with type 1 diabetes participated in a multicenter (nine sites in the United States, one site in Israel) pivotal trial. The Medtronic MiniMed® 670G system was used during a 2-week run-in phase without HCL control, or Auto Mode, enabled (Manual Mode) and, thereafter, with Auto Mode enabled during a 3-month study phase. A supervised hotel stay (6 days/5 nights) that included a 24-h frequent blood sample testing with a reference measurement (i-STAT) occurred during the study phase. Results: Adolescents (mean ± standard deviation [SD] 16.5 ± 2.29 years of age and 7.7 ± 4.15 years of diabetes) used the system for a median 75.8% (interquartile range [IQR] 68.0%–88.4%) of the time (2977 patient-days). Adults (mean ± SD 44.6 ± 12.79 years of age and 26.4 ± 12.43 years of diabetes) used the system for a median 88.0% (IQR 77.6%–92.7%) of the time (9412 patient-days). From baseline run-in to the end of study phase, adolescent and adult HbA1c levels decreased from 7.7% ± 0.8% to 7.1% ± 0.6% (P < 0.001) and from 7.3% ± 0.9% to 6.8% ± 0.6% (P < 0.001, Wilcoxon signed-rank test), respectively. The proportion of overall in-target (71–180 mg/dL) sensor glucose (SG) values increased from 60.4% ± 10.9% to 67.2% ± 8.2% (P < 0.001) in adolescents and from 68.8% ± 11.9% to 73.8% ± 8.4% (P < 0.001) in adults. During the hotel stay, the proportion of in-target i-STAT® blood glucose values was 67.4% ± 27.7% compared to SG values of 72.0% ± 11.6% for adolescents and 74.2% ± 17.5% compared to 76.9% ± 8.3% for adults. There were no severe hypoglycemic or diabetic ketoacidosis events in either cohort. Conclusions: HCL therapy was safe during in-home use by adolescents and adults and the study phase demonstrated increased time in target, and reductions in HbA1c, hyperglycemia and hypoglycemia, compared to baseline. Trial Registration: Clinicaltrials.gov identifier: NCT02463097.Keywords
This publication has 36 references indexed in Scilit:
- Exploration of the Performance of a Hybrid Closed Loop Insulin Delivery Algorithm That Includes Insulin Delivery Limits Designed to Protect Against HypoglycemiaJournal of Diabetes Science and Technology, 2016
- Hybrid Closed-Loop Insulin Delivery in Type 1 Diabetes During Supervised Outpatient ConditionsJournal of Diabetes Science and Technology, 2016
- Artificial Pancreas Device Systems for the Closed-Loop Control of Type 1 DiabetesJournal of Diabetes Science and Technology, 2015
- Feasibility of Outpatient 24-Hour Closed-Loop Insulin DeliveryDiabetes Care, 2015
- Day and Night Closed-Loop Control Using the Integrated Medtronic Hybrid Closed-Loop System in Type 1 Diabetes at Diabetes CampDiabetes Care, 2015
- Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic RegistryDiabetes Care, 2015
- Feasibility of a Portable Bihormonal Closed-Loop System to Control Glucose Excursions at Home Under Free-Living Conditions for 48 HoursDiabetes Technology & Therapeutics, 2014
- Threshold-Based Insulin-Pump Interruption for Reduction of HypoglycemiaThe New England Journal of Medicine, 2013
- Effect of Insulin Feedback on Closed-Loop Glucose Control: A Crossover StudyJournal of Diabetes Science and Technology, 2012
- Fully Integrated Artificial Pancreas in Type 1 DiabetesDiabetes, 2012